ArticleIndian dermatology online journal
Efficacy of Intermittent Fasting in the Management of Chronic Plaque Psoriasis: A Phase IIb Clinical Trial.
Article in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Intermittent fasting triggers interorgan communication to improve the progression of diabetic osteoporosis.Gut microbes · 2025Article
- Psoriasis Comorbidities: Obesity, Diet, and Metabolic Syndrome.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dietary measures have been used as an adjunctive therapy in the management of psoriasis. Intermittent fasting (IF) is an eating pattern in which energy is not consumed for a fixed duration, resulting in metabolic switch from liver-derived glucose to adipose-derived ketones. The data regarding effectiveness of IF in psoriasis are limited. Aim and Objectives: The aim of this study was to assess efficacy of IF in patients with chronic plaque psoriasis. The primary outcome of the study was change in psoriasis severity as measured by psoriasis area and severity index (PASI) at 28 weeks. The secondary outcome measures were change in metabolic parameters and biomarkers for atherosclerosis in each group. Patients and Methods: The study was designed as a randomized parallel group trial. Clinical parameters, psoriasis severity, fasting and postprandial blood sugar, lipid profile, high sensitivity C-reactive protein (hsCRP), vascular endothelial growth factor (VEGF), and interleukin 6 (IL-6), were measured using standard methods at baseline, 16 weeks, and 28 weeks. Patients were randomized to receive methotrexate in the dose of 0.3 mg/Kg/week with or without intermittent fasting. Results: A total of 120 patients were randomized in two groups of 60 each: group 1 (methotrexate) and group 2 (methotrexate and intermittent fasting). The mean age, mean duration of disease, PASI, and dermatology life quality index (DLQI) in group 1 were 45.5 (±12.9) years, 5.06 (±5.5) years, 17.1 (±6.7), and 12.33 (±5), respectively. The mean age, mean duration of disease, PASI, and DLQI in group 2 were and 42.9 (±14.6) years, 6.91 (±6.2) years, 16 (±4.3), and 11.9 (±4.3), respectively. There was no statistically significant difference in baseline parameters in two groups. In both the groups, there was a statistically significant difference in PASI, DLQI, VEGF, and hsCRP from baseline to 16 and 28 weeks. At week 16, 44 (73.3%) patients in group 1 and 47 (78.3%) in group 2 achieved PASI50 ( Limitations: The small sample size and loss to follow-up are major limitations of the study. Conclusion: Intermittent fasting using 16: 8 protocol is easy to perform and a safe and effective adjuvant for managing severe chronic plaque psoriasis. It helps in maintaining remission and results in improvement in metabolic parameters and markers of vascular inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.